The second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Its use enables key processes such as early access, regulatory approval, and reimbursement listing.
How PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Life sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
First-party insights bridge marketing and sales to deliver better HCP experiences.
Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.
How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
AstraZeneca’s Niko Andre discusses the power of patient partnership in driving medical progress.
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Portals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.
Congress and our nation’s public health officials should take the current moment to self-reflect and resolve challenges with public confidence in our public and scientific institutions.
Outlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.
The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
If the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.
Practices to ensure accuracy in selected datasets.
Scott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.
Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.
How pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Growing business segment of life sciences industry improves patient access.
More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Brexit and the pandemic continue to complicate flow of international talent.
Digital transformation is no stranger in the life sciences industry.
When it comes to vaccine hesitancy or reluctance, there have always been concerns around the public's belief and attitude. This is especially apparent among blacks and other minority groups, whose concerns can stem from historic injustices that fueled mistrust. The COVID era has presented an opportunity to convert many who are ready to engage via transparency and by initiating trust through marketing.
This month is as good a time as any to take a deep look at the transformations taking place in point-of-care delivery.
China‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.